{"commentary":{"count":7,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4,"youtube":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT03194542","nct_id":"NCT03194542","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03194542. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Subjects across each of the cohorts (Cohort 1, Cohort 2, Cohort 3A, and Cohort 3B) will receive luspatercept.","label":"Luspatercept in subjects with MPN-associated myelofibrosis","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-07-18","type":"ACTUAL"},"conditions":["Primary Myelofibrosis","Anemia"],"enrollment":{"count":95,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Luspatercept","type":"DRUG"}],"last_update":"2023-08-24","lead_sponsor":"Celgene","official_title":"A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-07-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"The Number of Participants With Anemia Responses Over Any 84-Day Period During the Primary Treatment Period","timeFrame":"Any consecutive \"rolling\" 84-day period from Day 1 through and including Day 168"}],"references":[{"citation":"Gerds AT, Harrison C, Kiladjian JJ, Mesa R, Vannucchi AM, Komrokji R, Bose P, Kremyanskaya M, Mead AJ, Gotlib J, Rose S, Sanabria F, Marsousi N, Giuseppi AC, Jiang H, Palmer JM, McCaul K, Ribrag V, Passamonti F. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv. 2024 Sep 10;8(17):4511-4522. doi: 10.1182/bloodadvances.2024012939.","pmid":"38820422","type":"DERIVED"}],"start_date":{"date":"2017-11-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence","url":"https://clinicaltrials.gov/study/NCT03194542"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03194542"}